JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3551
Zentalis Pharmaceuticals
ZNTL
$239M
| $1.59M | ﹤0.01% |
56,700
-48,879
| -46% | -$1.29M |
2020 Q2
8 quarters
|
|
3552
CALL
W.W. Grainger
GWW
$60.3B
| $1.59M | ﹤0.01% |
+3,500
| New | +$1.7M |
2022 Q2
0 quarters
|
|
3553
PUT
Dollar Tree
DLTR
$21B
| $1.59M | ﹤0.01% |
10,200
+10,000
| +5,000% | +$1.58M |
2021 Q2
4 quarters
|
|
|
HNGR
3554
DELISTED
Hanger Inc.
HNGR
| $1.59M | ﹤0.01% |
110,882
+4,930
| +5% | +$80K |
2019 Q1
13 quarters
|
|
|
HUGS
3555
DELISTED
USHG Acquisition Corp.
HUGS
| $1.59M | ﹤0.01% |
161,856
| – | – |
2021 Q3
3 quarters
|
|
|
SCWX
3556
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $1.58M | ﹤0.01% |
145,855
-8,567
| -6% | -$97.4K |
2016 Q3
23 quarters
|
|
|
WOW
3557
DELISTED
WideOpenWest
WOW
| $1.58M | ﹤0.01% |
86,881
+28,184
| +48% | +$566K |
2017 Q4
18 quarters
|
|
3558
PUT
NetApp
NTAP
$44.4B
| $1.58M | ﹤0.01% |
24,200
| – | – |
2021 Q3
3 quarters
|
|
|
FLNA
3559
Filana Therapeutics
FLNA
$45M
| $1.57M | ﹤0.01% |
55,866
+27,148
| +95% | +$686K |
2020 Q2
8 quarters
|
|
3560
Beyond Meat
BYND
$142M
| $1.57M | ﹤0.01% |
2,184
+884
| +68% | +$847K |
2019 Q2
12 quarters
|
|
|
SCPL
3561
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
| $1.56M | ﹤0.01% |
112,043
+81,523
| +267% | +$1.09M |
2021 Q4
2 quarters
|
|
|
CERE
3562
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.56M | ﹤0.01% |
59,113
+10,907
| +23% | +$310K |
2021 Q1
5 quarters
|
|
3563
PUT
TSMC
TSM
$2.45T
| $1.56M | ﹤0.01% |
19,100
+1,700
| +10% | +$157K |
2021 Q1
5 quarters
|
|
3564
Oscar Health
OSCR
$9.55B
| $1.56M | ﹤0.01% |
367,031
+348,002
| +1,829% | +$2.21M |
2021 Q2
4 quarters
|
|
3565
Invesco Actively Managed Exch-Traded Commodity Fd Tr Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF
PDBC
$7.78B
| $1.56M | ﹤0.01% |
86,461
-411,808
| -83% | -$7.84M |
2021 Q1
5 quarters
|
|
|
CPAR
3566
DELISTED
Catalyst Partners Acquisition Corp. Class A Ordinary Share
CPAR
| $1.56M | ﹤0.01% |
160,000
-109,885
| -41% | -$1.07M |
2022 Q1
1 quarter
|
|
3567
Standard Motor Products
SMP
$838M
| $1.55M | ﹤0.01% |
34,443
+5,761
| +20% | +$239K |
2013 Q2
36 quarters
|
|
3568
Wave Life Sciences
WVE
$745M
| $1.55M | ﹤0.01% |
477,110
-402,528
| -46% | -$774K |
2017 Q3
19 quarters
|
|
|
HRT
3569
DELISTED
HireRight Holdings Corporation
HRT
| $1.54M | ﹤0.01% |
108,568
-199,588
| -65% | -$3.11M |
2021 Q4
2 quarters
|
|
3570
Oramed Pharmaceuticals
ORMP
$187M
| $1.54M | ﹤0.01% |
336,549
+318,801
| +1,796% | +$1.7M |
2021 Q2
4 quarters
|
|
3571
Merchants Bancorp
MBIN
$2.29B
| $1.54M | ﹤0.01% |
67,944
-2,946
| -4% | -$71.8K |
2017 Q4
18 quarters
|
|
3572
Surgery Partners
SGRY
$1.74B
| $1.54M | ﹤0.01% |
53,230
+16,097
| +43% | +$703K |
2016 Q4
22 quarters
|
|
3573
PUT
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$21.7B
| $1.54M | ﹤0.01% |
22,400
-205,000
| -90% | -$16.2M |
2020 Q4
6 quarters
|
|
3574
HBT Financial
HBT
$1.32B
| $1.54M | ﹤0.01% |
85,991
-4,050
| -4% | -$71.2K |
2019 Q4
10 quarters
|
|
3575
Insteel Industries
IIIN
$572M
| $1.54M | ﹤0.01% |
45,656
+2,582
| +6% | +$103K |
2016 Q4
22 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.